The latest news:

• Medicenna’s Immunotherapy Phase 2b Trial Underway Using Brainlab Drug Delivery Technology         [Disclosure - this company is a sponsor of the Musella Foundation|    It looks like the technology to get the drug in the correct spot at the right concentration is finally here. Follow the link in the press release to the background info on the delivery system.  And this may be the right drug to use. In an earlier study, in recurrent GBM patients, they had a few complete responders, with some still  alive 4 years later.  
  



• Five years before brain cancer diagnosis, changes detectable in blood         This is a major find.  It may lead to a simple blood test to predict risk of developing a brain tumor - and perhaps even lead to research on how to stop the formation of the brain tumor if you know it is coming!
  



• New Target Found to Attack an Incurable Brain Tumor in Children         75% of pediatric DIPG patients have this - and there is a drug available against it which can be used off label. Hope they quickly start trials on DIPG kids.
  



• Estimating the annual frequency of synchronous brain metastasis in the United States 2010–2013: a population-based study         Not enough attention is being paid to metastatic brain tumors.  They are much more common than the primary brain tumors.   The Musella Foundation is listed as a sponsor of this research!  Good work!
  

BrainTumor Co-Payment Assistance Program Status:

• OPEN to new applicants